Literature DB >> 9087492

Treatment of experimental pneumonia due to penicillin-resistant Streptococcus pneumoniae in immunocompetent rats.

J Gavaldà1, J A Capdevila, B Almirante, J Otero, I Ruiz, M Laguarda, H Allende, E Crespo, C Pigrau, A Pahissa.   

Abstract

A model of pneumonia due to Streptococcus pneumoniae resistant to penicillin was developed in immunocompetent Wistar rats and was used to evaluate the efficacies of different doses of penicillin, cefotaxime, cefpirome, and vancomycin. Adult Wistar rats were challenged by intratracheal inoculation with 3 x 10(9) CFU of one strain of S. pneumoniae resistant to penicillin (MICs of penicillin, cefotaxime, cefpirome, and vancomycin, 2, 1, 0.5, and 0.5 microg/ml, respectively) suspended in brain heart broth supplemented with 0.7% agar. The rats experienced a fatal pneumonia, dying within 5 days and with peak mortality (70 to 80%) occurring 48 to 72 h after infection, and the bacterial counts in the lungs persisted from 8.87 +/- 0.3 log10 CFU/g of lung at 24 h of the infection to 9.1 +/- 0.3 log10 CFU/g at 72 h. Four hours after infection the animals were randomized into the following treatment groups: (i) control without treatment, (ii) penicillin G at 100,000 IU/kg of body weight every 2 h, (iii) penicillin G at 250,000 IU/kg every 2 h, (iv) cefotaxime at 100 mg/kg every 2 h, (v) cefpirome at 200 mg/kg every 2 h, and (vi) vancomycin at 50 mg/kg every 8 h. Two different protocols were used for the therapeutic efficacy studies: four doses of beta-lactams and one dose of vancomycin or eight doses of beta-lactams and two doses of vancomycin. Results of the therapy for experimental pneumonia caused by penicillin-resistant S. pneumoniae showed that initially, all the antimicrobial agents tested had similar efficacies, but when we prolonged the treatment, higher doses of penicillin, cefotaxime, and cefpirome were more effective than penicillin at lower doses in decreasing the residual bacterial titers in the lungs. Also, when we extended the treatment, vancomycin was more efficacious than penicillin at lower doses but was less efficacious than higher doses of penicillin or cefpirome. The model that we have developed is simple and amenable for inducing pneumonia in immunocompetent rats and could be used to explore the pathophysiology and to evaluate optimal therapy of this infection in the immunocompetent host.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9087492      PMCID: PMC163797     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  35 in total

1.  Emergence of multiply resistant pneumococci.

Authors:  M R Jacobs; H J Koornhof; R M Robins-Browne; C M Stevenson; Z A Vermaak; I Freiman; G B Miller; M A Witcomb; M Isaäcson; J I Ward; R Austrian
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

2.  Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Authors:  K Tateda; K Takashima; H Miyazaki; T Matsumoto; T Hatori; K Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

3.  Increased resistance to penicillin of pneumococci isolated from man.

Authors:  D Hansman; H Glasgow; J Sturt; L Devitt; R Douglas
Journal:  N Engl J Med       Date:  1971-01-28       Impact factor: 91.245

4.  Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum.

Authors:  J Gavaldà; P J Cardona; B Almirante; J A Capdevila; M Laguarda; L Pou; E Crespo; C Pigrau; A Pahissa
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.

Authors:  J D Knudsen; N Frimodt-Møller; F Espersen
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

6.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  P Moine; E Vallée; E Azoulay-Dupuis; P Bourget; J P Bédos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

7.  Streptococcus pneumoniae resistant to penicillin and chloramphenicol.

Authors:  P C Appelbaum; A Bhamjee; J N Scragg; A F Hallett; A J Bowen; R C Cooper
Journal:  Lancet       Date:  1977-11-12       Impact factor: 79.321

8.  Treatment of experimental endocarditis due to penicillin-resistant Streptococcus pneumoniae.

Authors:  M L Fernández Guerrero; F Arbol; C Verdejo; R Fernández Roblas; F Soriano
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

9.  Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain.

Authors:  R Pallares; J Liñares; M Vadillo; C Cabellos; F Manresa; P F Viladrich; R Martin; F Gudiol
Journal:  N Engl J Med       Date:  1995-08-24       Impact factor: 91.245

10.  In vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolates.

Authors:  A L Barry; S D Brown; W J Novick
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

View more
  8 in total

1.  Direct examination and cultures of bronchoalveolar lavage in pneumonia diagnosis: a comparative experimental study.

Authors:  Nilton Brandão da Silva; Lucas Martins; Frederico Martins; José Anflor; Tiago Tonietto; Cristiano Koefender; Paulo G Cardoso; José Moreira
Journal:  Intensive Care Med       Date:  2007-08-03       Impact factor: 17.440

2.  Pharmacodynamic assessment of cefprozil against Streptococcus pneumoniae: implications for breakpoint determinations.

Authors:  D P Nicolau; C O Onyeji; M Zhong; P R Tessier; M A Banevicius; C H Nightingale
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics.

Authors:  L Piroth; L Martin; A Coulon; C Lequeu; M Duong; M Buisson; H Portier; P Chavanet
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Penicillin pharmacodynamics in four experimental pneumococcal infection models.

Authors:  H Erlendsdottir; J D Knudsen; I Odenholt; O Cars; F Espersen; N Frimodt-Møller; K Fuursted; K G Kristinsson; S Gudmundsson
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  Efficacies of ABT-773, a new ketolide, against experimental bacterial infections.

Authors:  M J Mitten; J Meulbroek; M Nukkala; L Paige; K Jarvis; A Oleksijew; A Tovcimak; L Hernandez; J D Alder; P Ewing; Y S Or; Z Ma; A M Nilius; K Mollison; R K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

6.  Aerosol infection model of tuberculosis in wistar rats.

Authors:  Sheshagiri Gaonkar; Sowmya Bharath; Naveen Kumar; V Balasubramanian; Radha K Shandil
Journal:  Int J Microbiol       Date:  2010-03-18

Review 7.  Management of infections due to antibiotic-resistant Streptococcus pneumoniae.

Authors:  S L Kaplan; E O Mason
Journal:  Clin Microbiol Rev       Date:  1998-10       Impact factor: 26.132

8.  Is Penicillin Plus Gentamicin Synergistic Against Sessile Group B Streptococcal Isolates? An in Vivo Study With an Experimental Model of Foreign-Body Infection.

Authors:  Corinne Ruppen; Thomas Mercier; Denis Grandgirard; Stephen L Leib; Cristina El Haj; Oscar Murillo; Laurent Decosterd; Parham Sendi
Journal:  Front Microbiol       Date:  2018-05-15       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.